Cargando…

Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization

Oncolytic virotherapies, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects. The OPTiM trial, in particular, demonstrated the superior anti-cancer effects of T-VEC as compared to systemic immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, Tyler, Craig, Morgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880985/
https://www.ncbi.nlm.nih.gov/pubmed/31774808
http://dx.doi.org/10.1371/journal.pcbi.1007495

Ejemplares similares